Skip to content

Acoustic Radiation Force Impulse (ARFI)Technology in Prediction of Liver Fibrosis

Clinical Application of Acoustic Radiation Force Impulse (ARFI)Technology in Prediction of Liver Fibrosis in HBV and HCV-infected Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01268865
Acronym
ARFI
Enrollment
200
Registered
2010-12-31
Start date
2010-12-31
Completion date
Unknown
Last updated
2011-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Fibrosis

Keywords

Acoustic Radiation Force Impulse (ARFI), Virtual Touch Quantification (VTQ), liver stiffness measurement (LSM), liver fibrosis, cirrhosis, hepatitis B, hepatitis C

Brief summary

Background: In patients with chronic liver diseases, liver fibrosis staging is crucial for hazard evaluation of future disease complication development and thus for the optimal decision making on treatment selections.In the era of antiviral and antifibrotic treatments, clinical and research demands are also increasing for non-invasive surveillance of liver fibrosis to evaluate the progression or regression. However, local baseline data on liver stiffness measurement (LSM) using ARFI technique is still lacking in Taiwan, where viral hepatitides are highly endemic. Aim: Using the ARFI elastosonography, we are dedicated to the aims to recruit patients based on strict but appropriate criteria, to complete the correlation and validity studies between ARFI quantification and the referenced METAVIR fibrosis scoring and to conduct subsequent innovative studies on liver diseases. Materials and Methods: We plan to perform the ARFI quantification for each HBV or HCV-infected patient immediately followed by priorly scheduled conventional liver biopsy for METAVIR scoring during the same session of examination. Statistics: The first year's study using ARFI will focus on the correlation testings and validity studies using receiver operating characteristics.

Detailed description

Contribution and Future Works: Using the ARFI quantification either as a causal factor or as a outcome, we can conduct future analyses ranging from validations, regressions to prospective time-to-event analysis among our cohorts.

Interventions

None listed

Sponsors

China Medical University Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* infected with HBV only or HCV only

Exclusion criteria

* concurrent HBV-HCV infection, etc.

Countries

Taiwan

Contacts

Primary ContactSheng-Hung Chen, MD
shcvghtc@gmail.com886-4-22052121

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026